2Y7X
The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
Summary for 2Y7X
Entry DOI | 10.2210/pdb2y7x/pdb |
Related | 1C5M 1EZQ 1F0R 1F0S 1FAX 1FJS 1G2L 1G2M 1HCG 1IOE 1IQE 1IQF 1IQG 1IQH 1IQI 1IQJ 1IQK 1IQL 1IQM 1IQN 1KSN 1KYE 1LPG 1LPK 1LPZ 1LQD 1MQ5 1MQ6 1MSX 1NFU 1NFW 1NFX 1NFY 1NL8 1P0S 1V3X 1WU1 1XKA 1XKB 1Z6E 2BMG 2BOH 2BOK 2BQ6 2BQ7 2BQW 2CJI 2FZZ 2G00 2GD4 2J2U 2J34 2J38 2J4I 2J94 2J95 2JKH 2UWL 2UWO 2UWP 2VH0 2VH6 2VVC 2VVU 2VVV 2VWL 2VWM 2VWN 2VWO 2W26 2W3I 2W3K 2WYG 2WYJ 2XBV 2XBW 2XBX 2XBY 2XC0 2XC4 2XC5 2Y5F 2Y5G 2Y5H 2Y7Z 2Y80 2Y81 2Y82 |
Descriptor | ACTIVATED FACTOR XA HEAVY CHAIN, FACTOR X LIGHT CHAIN, 6-CHLORO-N-[(3S)-1-(5-FLUORO-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL)-2-OXO-PYRROLIDIN-3-YL]NAPHTHALENE-2-SULFONAMIDE, ... (6 entities in total) |
Functional Keywords | blood clotting, hydrolase, serine protease |
Biological source | HOMO SAPIENS (HUMAN) More |
Cellular location | Secreted: P00742 P00742 |
Total number of polymer chains | 2 |
Total formula weight | 44299.72 |
Authors | Watson, N.S.,Adams, C.,Belton, D.,Brown, D.,Burns-Kurtis, C.L.,Chaudry, L.,Chan, C.,Convery, M.A.,Davies, D.E.,Exall, A.M.,Harling, J.D.,Irving, W.R.,Irvine, S.,Kleanthous, S.,McLay, I.M.,Pateman, A.J.,Patikis, A.N.,Roethka, T.J.,Senger, S.,Stelman, G.J.,Toomey, J.R.,West, R.I.,Whittaker, C.,Zhou, P.,Young, R.J. (deposition date: 2011-02-02, release date: 2011-03-16, Last modification date: 2024-10-16) |
Primary citation | Watson, N.S.,Adams, C.,Belton, D.,Brown, D.,Burns-Kurtis, C.L.,Chaudry, L.,Chan, C.,Convery, M.A.,Davies, D.E.,Exall, A.M.,Harling, J.D.,Irvine, S.,Irving, W.R.,Kleanthous, S.,Mclay, I.M.,Pateman, A.J.,Patikis, A.N.,Roethke, T.J.,Senger, S.,Stelman, G.J.,Toomey, J.R.,West, R.I.,Whittaker, C.,Zhou, P.,Young, R.J. The Discovery of Potent and Long-Acting Oral Factor Xa Inhibitors with Tetrahydroisoquinoline and Benzazepine P4 Motifs. Bioorg.Med.Chem.Lett., 21:1588-, 2011 Cited by PubMed Abstract: The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. PubMed: 21349711DOI: 10.1016/J.BMCL.2011.01.129 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report